The bill aims to entice drug makers to lower their list prices to 2021 net Medicare rates by blocking pharmacy benefit managers from accepting drug rebates or other discounts.
The bill aims to entice drug makers to lower their list prices to 2021 net Medicare rates by blocking pharmacy benefit managers from accepting drug rebates or other discounts.
